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Introduction: Activation of inflammation and coagulation was closely related and mutually interdependent in
sepsis. Tissue factor (TF) and its endogenous inhibitor, tissue factor pathway inhibitor (TFPI) was the main regulators
of the initiation of coagulation process. Altered plasma levels of TF and TFPI have been related to worse outcome
in sepsis. The objective of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the TF
and TFPI genes were associated with risk and outcome for patients with severe sepsis.
Methods: Seventeen SNPs in TF and TFPI were genotyped in samples of sepsis (n =577) and severe sepsis patients
(n =476), and tested for association in this case–control collection. We then investigated correlation between the
associated SNPs and the mRNA expression, and protein level of the corresponding gene. The mRNA levels of TF
were determined using real-time quantitative reverse transcription-polymerase chain reaction and the soluble
plasma levels of TF were measured using enzyme linked immunosorbent assay (ELISA) method.
Results: Association analysis revealed that three TF SNPs in perfect linkage disequilibrium, rs1361600, rs3917615 and
rs958587, were significantly associated with outcome of severe sepsis. G allele frequency of rs1361600 in survivor
patients was significantly higher than that in nonsurvivor severe sepsis patients (P =4.91 × 10-5, odds ratio (OR) =0.48,
95% confidence interval (CI) 0.33 to 0.69). The association remained significant after adjustment for covariates in multiple
logistic regression analysis and for multiple comparisons. Lipopolysaccharide-induced TF-mRNA expression levels in
peripheral blood mononuclear cells from subjects carrying rs1361600 AG and GG genotypes, were significantly lower
than those subjects carrying AA genotype (P =0.0012). Moreover, severe sepsis patients of GG and GA genotypes showed
lower serum levels of TF than patients with AA genotype (Padj =0.02). The plasma levels of TF were also associated with
outcome of severe sepsis patients (Padj =0.01). However, genotype and allele analyses did not show any significant
difference between sepsis and severe sepsis patients.
Conclusions: Our findings indicate that common genetic variation in TF was significantly associated with outcome of
severe sepsis in Chinese Han population.Introduction
Sepsis is an infection-initiated and inflammation-induced
syndrome [1]. Despite progress in the development of
antibiotics and other supportive care therapies, severe
sepsis remains an unconquered challenge for clinicians
with an unacceptable high mortality rate of 30 to 50%
[2]. Although the pathogenesis of severe sepsis is not* Correspondence: zhenjusong@yahoo.com; tong.chaoyang@zs-hospital.sh.cn
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exaggerated and uncontrolled systemic host inflammation
and coagulation response to infectious pathogens leads to
microvascular thrombosis, multiple organ dysfunction
syndrome and death in severe sepsis [3].
Tissue factor (TF) and its endogenous inhibitor, tissue
factor pathway inhibitor (TFPI), are the main regulators
of the initiation of coagulation process [4,5]. The balance
between TF and TFPI is essential in hemostasis and an
alteration of this equilibrium may induce a procoagulant
state. Recent studies indicated that the dysfunction of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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outcome of sepsis [6,7]. TF is not normally expressed
by circulating blood cells or by vascular endothelial cells.
During sepsis, a variety of stimuli such as proinflammatory
cytokines and shear stress induce TF expression on
monocytes and endothelial cells [8]. Factor VIIa binds to
TF on the cell surface, forming TF/factor VIIa complexes.
The complexes then bind to factor X, converting it to the
activated form factor Xa, which leads to eventual thrombin
formation and fibrin deposition [9-11]. Normally, thrombin
generation via the TF pathway is controlled rapidly by TFPI.
As the main regulator in the initial step of the coagulation
cascade mediated by TF, TFPI binds to coagulation factors
Xa and VIIa and TF and forms an inactive complex. It has
been reported that the lower TFPI levels were strongly
correlated with organ dysfunction as well as worse
outcome of severe sepsis [6]. Furthermore, experimental
studies proved the benefit of the early blockade of the
TF–factor VIIa activated coagulation system in reducing
both systemic and pulmonary inflammation as well as
coagulation, and in improving lung physiology, histological
results and even survival [12,13].
Sepsis is a complex syndrome resulting from the inter-
actions between environmental factors and genetic factors.
Clinical studies found that individuals varied significantly
in their susceptibility to infection and in their ability to
recover from apparently similar infectious processes. These
differences can be partially explained by polymorphisms of
the genes encoding proteins involved in mediating and
controlling the innate immune response, the inflammatory
cascade, coagulation and fibrinolysis [14]. Despite the
prognostic value of hemostatic abnormalities in sepsis and
the description of several hemostatic gene polymorphisms,
only a few association studies sought to correlate these
single nucleotide polymorphisms (SNPs) (mainly the
factor V Leiden mutations and the 4G genotype in the
promoter region of plasminogen activator inhibitor-1) with
susceptibility to severe sepsis and disease severity [15-17].
In recent years, several polymorphisms in the promoter
and coding region of the TF and TFPI genes have been
identified, and some were associated with an increased risk
of adverse outcomes in illnesses such as deep venous
thrombosis, stroke and cardiovascular disease [18-21].
However, the relationship between genetic polymorphisms
of TF and TFPI and survival in patients with severe sepsis
has not been examined.
Given the potential association of an activated coagulation
system with sepsis pathophysiology, particularly the role of
the TF pathway as an important initiator of the coagulation
system, TF and TFPI were excellent candidate genes
for severe sepsis susceptibility. The objective of this study
was thus to evaluate the association of TF and TFPI
polymorphisms with the development and outcome of
severe sepsis in the Chinese Han population. To gainfurther insight into the possible molecular basis of
the association, we examined the functional influence
in vitro of associated polymorphisms in the regulatory
region of TF.
Materials and methods
Study design and enrollment
This study was approved by the Ethics Study Board of
Zhongshan Hospital, Fudan University, Shanghai, China
(record number 2006-23). Written informed consent was
obtained from patients or the next of kin, carers or guard-
ians on the behalf of the participants before enrollment.
The diagnosis of sepsis, severe sepsis and septic shock was
established according to the 2001 SCCM/ESICM/ACCP/
ATS/SIS International Sepsis Definitions Conference [22]
(Additional file 1). In this study, septic shock patients were
classified as the severe sepsis group. Baseline characteristics
(age, gender and previous health status) as well as
clinical data including Acute Physiology and Chronic
Health Evaluation II (APACHE II) and Sequential Organ
Failure Assessment (SOFA) scores, source of infection,
microbiology and ICU mortality were obtained after the
patient met the sepsis criteria. The APACHE II and SOFA
scores were calculated in the first 24 hours after the
diagnosis of sepsis and severe sepsis. When cultures
were absent or negative, the source of infection was
determined by two senior physicians. All patients included
in the study were followed up for 30 days or to hospital
discharge. The discharged patients hospitalized for less than
30 days were followed up once a week by telephone until
they were diagnosed at day 60. People that could not be
contacted by our team worker were excluded from the
study. Exclusion criteria included age below 18 years,
pregnancy, severe chronic respiratory disease, severe
chronic liver disease (defined as Child–Pugh score >10),
malignancy, using of high-dose immunosuppressive therapy
and AIDS diagnosis.
Recent analyses by genome-wide SNP variation showed
that the central Han Chinese could be regarded as one
single homogeneous population [23]. To reduce the poten-
tial confounding from ethnic backgrounds, we only enrolled
people with self-reported origin of central Han Chinese,
including indigenous people from Zhejiang Province,
Jiangsu Province, Anhui Province and Shanghai City.
Single nucleotide polymorphism selection and
genotyping
Tag SNPs were selected based on the data of Han Chinese
in Beijing from the HapMap project phase II. The tag
SNPs covered the gene regions and up to 1 kb of 3′ as
well as 5′ flanking regions of the candidate genes. Four
tag SNPs for the 12.44 kb region encompassing the entire
TF gene and eight tag SNPs for the 75.91 kb region
encompassing the entire TFPI gene were identified by
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ging criteria: pairwise tagging of the HapMap Han
Chinese in Beijing population with r2 ≥ 0.8 and a
minor allele frequency ≥5%. Additionally, five SNPs
located within the gene region were also genotyped in
this study as they showed association with deep ven-
ous thrombosis and ischemic arterial disease. A total
of 17 SNPs were selected and genotyped in this study.
The location and characterization of all selected SNPs are
presented in Additional file 2.
Genomic DNA was extracted from whole blood with a
FlexiGene DNA Kit (Qiagen, Hilden, Germany) in accord-
ance with the protocol of the manufacturer. We genotyped
these SNPs using the 12-plex GenomeLab SNPStream sys-
tem (Beckman Coulter, California, USA). The primers for
PCR and single base extension were designed with Beckman
Coulter Autoprimer software and are presented in
Additional file 3. Genotyping was carried out blind to
case–control status. One duplicate sample was added
to each 96-well sample plate for quality assurance and qual-
ity control validation of inter-plate discordance, and we
placed an extra 10 duplicates into our sample set in order
to test for experiment-wide discordance. The quality of the
genotype data was assessed by testing for Hardy–Weinberg
equilibrium using the chi-square distribution for each assay.
The overall genotype call rate was 97%, and the accuracy
was 99.96% according to duplicate analysis.
Isolation and stimulation of cells from healthy subjects
To determine the associations between rs1361600
genotypes and TF mRNA levels in peripheral blood
mononuclear cells (PBMCs), we investigated 45 subjects
with the rs1361600AA genotype, 42 subjects with the GA
genotype and three subjects with the GG genotype. All
the subjects were healthy volunteers. PBMCs were derived
using Ficoll gradient density centrifugation method.
Isolated PBMCs were plated at a density of 1 × 106 cells/ml
in 24-well plates and cultured in RPMI 1640 medium with
10% fetal bovine serum at 37°C with 5% carbon dioxide.
The cells were then incubated for 6 hours in the presence
of 100 ng/ml Escherichia coli 0111:B4 lipopolysaccharide
(LPS; Sigma, Saint Louis, USA).
RNA purification and tissue factor mRNA expression analysis
Total RNA was extracted using the RNeasy Mini kit
(Qiagen). RNA (100 ng) was used for cDNA synthesis
using a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster, USA) according to the manu-
facturer’s protocol. Quantitative RT-PCR was per-
formed using SYBR Green (TaKaRa, Kyoto, Japan) on an
ABI PRISM 7900 Sequence Detector (Applied Biosystems,
Foster, USA) with SDS 2.1 software. Each reaction was per-
formed in triplicate, with final calculations resulting from
the means of triplicate wells. The ΔΔCq method was usedto determine the difference for the mean mRNA expression
levels of TF between study subjects with different genotypes
of rs1361600. For each individual, the relative expression
level ΔCq (Cq T – Cq E) of TF mRNA was normalized
with GAPDH and then transformed into a relative quantity
using the following formula, where ΔΔCq is for the individ-
ual and ΔCq is the calibrator:
Relative quantity ¼ 2–ΔΔCq
The primers for TF mRNA were: forward, 5′-CGCC
AACTGGTAGACATGG-3′; and reverse, 5′-AACCGGT
GCTCTCCACATT-3′. The primers for GAPDH were:
forward, 5′-TGAAGGTCGGAGTCAACGGATTTGGT-3′;
and reverse, 5′-CATGTGGGCCAT GAGGTCCACCAC-3′.
Serum collection and tissue factor level measurement
Blood samples (2 ml) were collected within 24 hours of
meeting the criteria for severe sepsis. Samples were cen-
trifuged at 4°C for 10 minutes at 3,200 rpm within 60 mi-
nutes after collection. The serum was then stored at
−80°C until use. TF protein levels were determined by
the human enzyme-linked immunosorbent assay kit
(R&D Systems, Minnesota, USA) according to the man-
ufacturer’s protocol.
Statistical analysis
The differences in allele and genotype distributions
between case and control groups were compared using
the chi-square test or Fisher’s exact test when appropriate.
The test for association with genotypes used the global
genotype test in the 3 × 2 contingency table. Allele
frequencies of cases and controls were used to calculate the
odds ratio and the 95% confidence interval. Multivariate
logistic regression was used to adjust for potential
confounding variables including age, gender, history
of disease, source of infection, APACHE II and SOFA
scores. The Bonferroni method was used to correct for
multiple comparisons where applicable. The power analysis
was performed using the Genetic Power Calculator web
tool. Two-tailed P <0.05 was considered statistically
significant, whereas corrected P < (0.05/number of tests)
was considered significant after Bonferroni correction.
Thirty-day survival curves were estimated using the
Kaplan–Meier method and their comparison related
to genotypes was performed with the log-rank test.
Continuous variables were described as the mean ± standard
deviation. Differences in relative mRNA expression and
protein levels of TF between the rs1361600AA and
GA+GG genotypes were evaluated by Mann–Whitney U
test. To determine whether an association with rs1361600
genotypes might depend on other potential confounding
factors for TF serum levels, we investigated the association
of rs1361600 genotypes by adding the polymorphisms to a
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APACHE II scores. The software used for statistical
calculations was SPSS 15.0 (SPSS Inc., Chicago, IL, USA)
unless specified.
Results
Characteristics of the study population
From May 2005 to December 2013, a total of 476 severe
sepsis patients (including 126 septic shock patients) and
577 sepsis patients were enrolled in this case–control
study. The baseline characteristics and clinical data of
all subjects are presented in Table 1. There were no
significant differences between the severe sepsis and
sepsis groups in age, gender, comorbidity, site of infection
and microorganism responsible. However, the length of
ICU stay and mean APACHE II and SOFA scores were
significantly higher in patients with severe sepsis than
those in patients with sepsis (P <0.05). The patients with
severe sepsis (35.3%) had significantly higher 30-day
mortality rate than patients with sepsis (6.9%). According
to the 30-day mortality, severe sepsis patients were divided
into survivor and nonsurvivor groups. The average age,
length of ICU stay and mean APACHE II and SOFATable 1 Demographic and clinical characteristics of the study
Sepsis patients Severe sepsis patie
Number 577 476
Age 62.6 ± 11.2 66.1 ± 11.5
Sex (male/female) 334/243 275/201
APACHE II score 10.4 ± 3.3 18.7 ± 4.8
Diabetes 50 (8.7%) 51 (10.7%)
Chronic liver disease 11 (1.9%) 17 (3.6%)
Chronic renal failure 18 (3.1%) 20 (4.2%)
Congestive heart failure 25 (4.3%) 32 (6.7%)
Chronic pulmonary disease 35 (6.1%) 42 (8.8%)
SOFA score 1.4 ± 0.3 8.1 ± 1.7
LOS (days) 8.5 ± 2.6 15.3 ± 8.6
Infection insult
Lung 380 (65.9%) 312 (65.5%)
Abdomen 151 (26.2%) 119 (25.0%)
Bloodstream 13 (2.3%) 17 (3.6%)
UTI 11 (1.9%) 12 (2.5%)
Others 22 (3.8%) 16 (3.4%)
Microbiology positivec 225 (39.0%) 195 (41.0%)
Gram-positive 96 (42.7%) 75 (38.5%)
Gram-negative 98 (43.6%) 81 (41.5%)
Fungi 15 (6.7%) 18 (9.2%)
Mixed 16 (7.1%) 21 (10.8%)
Data presented as mean ± standard deviation or number (%). APACHE, Acute Physio
applicable; SOFA, Sequential Organ Failure Assessment; UTI, urinary tract infection.
group. cIncluded relevant cultures from tissue sites, sputum, blood, urine, pleural anscores in the nonsurvivor group were higher than those
in the survivor group (P <0.05). However, the gender
proportion, comorbidity and site of infection between
the nonsurvivor and survivor groups did not show
any significant difference (P >0.05).
Association analyses of TF and TFPI polymorphisms with
susceptibility to severe sepsis
The distributions of TF and TFPI SNPs in the patients
with sepsis and severe sepsis are presented in Table 2.
All tested SNPs conformed to the Hardy–Weinberg
equilibrium in both groups (P >0.05). We compared the
allele and genotype distributions of all SNPs in TF and
TFPI between the sepsis and severe sepsis patients.
No significant difference was observed between the
two groups in either the unadjusted or adjusted
models (P >0.05). Assuming the prevalence of 0.01
and using a significance level of 0.05, our study had
over 99% power to detect association with rs1361600 in
577 sepsis patients versus 476 severe sepsis patients. These
results suggested that the TF and TFPI gene variants were
not associated with the susceptibility of severe sepsis in
Chinese Han populations.subjects
nts P valuea Survivors Nonsurvivors P valueb
NA 308 168 NA
0.07 62.6 ± 10.8 68.9 ± 13.7 0.04
0.56 180/128 98/70 0.98
0.007 14.6 ± 2.8 26.2 ± 7.1 0.008
0.26 33 (10.7%) 18 (10.7%) 1.00
0.10 9 (2.9%) 8 (4.8%) 0.30
0.35 12 (3.9%) 8 (4.8%) 0.65
0.09 20 (6.5%) 12 (7.1%) 0.79
0.09 25 (8.1%) 17 (10.1%) 0.46
<0.001 6.8 ± 1.8 10.5 ± 1.8 0.01
0.006 13.5 ± 7.3 15.1 ± 8.9 0.02
0.92 206 (66.9%) 106 (63.1%) 0.41
0.67 73 (23.7%) 46 (27.4%) 0.38
0.20 8(2.6%) 9 (5.4%) 0.12
0.50 9 (2.9%) 3 (1.8%) 0.45
0.70 12 (3.9%) 4 (2.4%) 0.38
0.52 114 (37.0%) 76 (45.2%) 0.08
0.38 47 (41.2%) 27 (35.5%) 0.43
0.68 47 (41.2%) 31 (40.8%) 0.95
0.33 10 (8.8%) 8 (10.5%) 0.69
0.19 10 (8.8%) 10 (13.2%) 0.34
logy and Chronic Health Evaluation; LOS, length of ICU stay; NA, not
aSepsis group versus severe sepsis group. bSurvivor group versus nonsurvivor
d peritoneal fluid.
Table 2 Association analysis of SNPs in TF and TFPI between the sepsis and severe sepsis groups
Gene Sepsis Severe sepsis Allelic comparison Genotypic comparison
SNP patients patients P1adj OR
1










rs1324214 0.13 0.86 (0.71 to 1.05) 0.22 0.89 (0.83 to 1.04) 0.09 0.14
CC 270 (47.8%) 253 (54.2%)
CT 270 (47.8%) 191 (40.9%)
TT 25 (4.4%) 23 (4.9%)
T 810 (71.7%) 697 (74.6%)
C 320 (28.3%) 237 (25.4%)
rs762484 0.22 0.86 (0.69 to 1.09) 0.36 0.89 (0.74 to 1.07) 0.07 0.12
TT 374 (66%) 330 (71%)
TC 185 (32.6%) 124 (26.7%)
CC 8 (1.4%) 11 (2.4%)
T 933 (82.3%) 784 (84.3%)
C 201 (17.7%) 146 (15.7%)
rs696619 0.31 0.91 (0.76 to 1.09) 0.46 0.93 (0.79 to 1.06) 0.14 0.26
AA 228 (40.7%) 192 (41.5%)
AG 271 (48.4%) 237 (51.2%)
GG 61 (10.9%) 34 (7.3%)
A 727 (64.9%) 621 (67.1%)
G 393 (35.1%) 305 (32.9%)
rs3917615 0.87 0.98 (0.80 to 1.21) 0.92 0.98 (0.83 to 1.18) 0.07 0.16
CC 344 (61.3%) 280 (59.5%)
CT 189 (33.7%) 179 (38%)
TT 28 (5%) 12 (2.5%)
C 877 (78.2%) 739 (78.5%)
T 245 (21.8%) 203 (21.5%)
rs1361600 0.53 0.94 (0.76 to 1.15) 0.72 0.95 (0.82 to 1.12) 0.07 0.16
AA 342 (60%) 280 (59.6%)
AG 198 (34.7%) 178 (37.9%)
GG 30 (5.3%) 12 (2.6%)
A 882 (77.4%) 738 (78.5%)
G 258 (22.6%) 202 (21.5%)
rs958587 0.62 0.95 (0.77 to 1.17) 0.78 0.96 (0.84 to 1.14) 0.06 0.15
CC 342 (60.4%) 279 (59.4%)
CT 194 (34.3%) 178 (38.0%)
TT 30 (5.3%) 12 (2.6%)
C 878 (77.6%) 736 (78.5%)
T 254 (22.4%) 202 (21.5%)
rs3917643 1.00 0.22 (0.25 to 6.05) 0.85 0.29 (0.32 to 5.26) 1.00 0.98
AA 570 (99.5%) 468 (99.4%)
AG 3 (0.5%) 3 (0.6%)
A 1143 (99.7%) 939 (99.7%)
G 3 (0.3%) 3 (0.3%)
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Table 2 Association analysis of SNPs in TF and TFPI between the sepsis and severe sepsis groups (Continued)
rs145977586 1.00 0.22 (0.25 to 6.05) 0.85 0.29 (0.32 to 5.26) 1.00 0.98
GG 570 (99.5%) 468 (99.4%)
GA 3 (0.5%) 3 (0.6%)
G 1143 (99.7%) 939 (99.7%)
A 3 (0.3%) 3 (0.3%)
TFPI
rs3755248 0.75 0.96 (0.75 to 1.23) 0.67 0.87 (0.71 to 1.18) 0.71 0.62
TT 412 (73%) 342 (73.4%)
TC 141 (25%) 118 (25.3%)
CC 11 (2%) 6 (12.9%)
T 965 (85.5%) 802 (86.1%)
C 163 (14.5%) 130 (13.9%)
rs3213739 0.46 1.07 (0.90 to 1.28) 0.32 1.15 (0.82 to 1.32) 0.79 0.56
GG 270 (47.7%) 218 (46.4%)
GT 156 (27.6%) 127 (27%)
TT 140 (24.7%) 125 (26.6%)
G 696 (61.5%) 563 (59.9%)
T 436 (38.5%) 377 (40.1%)
rs7594359 0.93 0.99 (0.78 to 1.25) 0.94 0.94 (0.79 to 1.18) 0.12 0.17
CC 389 (69.5%) 317 (68.2%)
CT 156 (27.9%) 143 (30.8%)
TT 15 (2.7%) 5 (1.1%)
C 934 (83.4%) 777 (83.5%)
T 186 (16.6%) 153 (16.5%)
rs10931292 0.92 0.99 (0.82 to 1.19) 0.82 0.78 (0.76 to 1.12) 0.14 0.12
TT 255 (44.9%) 222 (47.9%)
TC 253 (44.5%) 180 (38.9%)
CC 60 (10.6%) 61 (13.2%)
T 763 (67.2%) 624 (67.4%)
C 373 (32.8%) 302 (32.6%)
rs8176441 0.93 0.99 (0.81 to 1.21) 0.82 0.76 (0.56 to 1.48) 0.10 0.23
TT 300 (52.9%) 259 (55.7%)
TC 237 (41.8%) 170 (36.6%)
CC 30 (5.3%) 36 (7.7%)
T 837 (73.8%) 688 (74%)
C 297 (26.2%) 242 (26%)
rs12613071 0.84 1.02 (0.84 to 1.23) 0.75 1.24 (0.86 to 1.38) 0.98 0.95
TT 288 (50.9%) 233 (50.2%)
TC 224 (39.6%) 186 (40.1%)
CC 54 (9.5%) 45 (9.7%)
T 800 (70.7%) 652 (70.3%)
C 332 (29.3%) 276 (29.7%)
rs10153820 0.58 0.95 (0.79 to 1.14) 0.62 0.98 (0.81 to 1.12) 0.15 0.36
GG 254 (45.3%) 230 (49.4%)
GA 251 (44.7%) 181 (38.8%)
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AA 56 (10%) 55 (11.8%)
G 759 (67.6%) 641 (68.8%)
A 363 (32.4%) 291 (31.2%)
rs8176592 0.12 1.24 (0.94 to 1.63) 0.36 1.16 (0.97 to 1.58) 0.31 0.45
TT 461 (80.9%) 363 (77.1%)
TC 102 (17.9%) 100 (21.2%)
CC 7 (1.2%) 8 (1.7%)
T 1024 (89.8%) 826 (87.7%)
C 116 (10.2%) 116 (12.3%)
rs2192824 0.79 1.03 (0.83 to 1.27) 0.65 1.13 (0.92 to 1.46) 0.76 0.68
CC 354 (62.7%) 292 (62.7%)
CT 185 (32.7%) 148 (31.8%)
TT 26 (4.6%) 26 (5.6%)
C 893 (79%) 732 (78.5%)
T 237 (21%) 200 (21.5%)
Data presented as number (%) of subjects. P was determined using the chi-square test. Padj and ORadj came from multivariate logistic regression. P <0.0029 (0.05/
17) was considered statistically significant after Bonferroni correction. CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism; TF, tissue factor;
TFPI, tissue factor pathway inhibitor.
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outcome of severe sepsis
We next investigated the association between all tested
SNPs and 30-day mortality of patients with severe sepsis.
Three SNPs (rs1361600 (−603A/G), rs3917615 (−1322C/T)
and rs958587 (−1812C/T)) in the TF gene promoter region
were in complete linkage disequilibrium. The –603G/–
1322 T/–1812 T haplotype, presently defined as –603G
(rs1361600G), was significantly associated with lower
mortality at 30 days. As shown in Table 3, the minor allele
rs1361600G frequency was significantly more frequent in
survivors compared with nonsurvivors (P = 4.91 × 10-5,
odds ratio = 0.48, 95% confidence interval = 0.33 to 0.69),
even after Bonferroni correction for multiple comparisons
(P = 8.35 × 10-4 corrected for 17 SNPs tested). Furthermore,
using age, APACHE II and SOFA scores as covariates,
multiple logistic regression analysis showed that the
minor allele G was still significantly associated with
protection from severe sepsis fatal outcome (adjusted
P = 4.52 × 10-4, adjusted odds ratio = 0.57, 95% confidence
interval = 0.41 to 0.74). The genotype distribution of
rs1361600 was also significantly different between the
survivor and nonsurvivor groups (P = 2.42 × 10-5), and
the difference remained significant after adjustment for
age, APACHE II and SOFA scores in multiple logistic
regression analysis (adjusted P = 6.51 × 10-4) and for
multiple comparisons (P = 4.11 × 10-4 corrected for 17
SNPs tested). We then conducted a Kaplan–Meier sur-
vival analysis of different rs1361600 genotypes in patients
with severe sepsis at 30 days (Figure 1). Kaplan–Meier
survival curves showed strong significant differences
between the subjects who carried the AA genotypeand the subjects who carried AG + GG genotypes
(log-rank test, P =5.92 × 10-5). However, the SNPs in TFPI
were not associated with the outcome for severe sepsis
patients (P >0.05) (Table 3).
Association analyses of tissue factor mRNA expression
levels with rs1361600 genotypes
To evaluate the association between the rs1361600
genotype and TF mRNA levels in PBMCs, we selected
45 subjects with the rs1361600AA genotype, 42 subjects
with the AG genotype and three subjects with the GG
genotype, who were matched for age and sex. As shown in
Figure 2, the TF mRNA expression in PBMCs was signifi-
cantly lower in the subjects who carried AG+GG geno-
types compared with the subjects who carried AA genotype
after stimulation with LPS for 6 hours (P = 0.0012).
Association analyses of tissue factor plasma levels with
rs1361600 genotypes
To assess the influence of rs1361600 on plasma TF protein
levels, TF antigen of plasma was measured in 118 severe
sepsis patients, including 60 patients with the rs1361600AA
genotype, 55 patients with the AG genotype and three
patients with the GG genotype. Our results showed that
rs1361600AG+GG genotypes were associated with lower
TF serum concentrations on the first day of severe
sepsis. As shown in Figure 3, the patients with AG+GG
genotypes had lower plasma concentrations of TF than
AA subjects (1,945.6 ± 168.5 pg/ml vs. 2,124.3 ± 273.6 pg/ml,
P =0.005). To control confounding variables, we used
the possible confounding factors (age, APACHE II and
SOFA scores) as covariates in a linear regression model
Table 3 Association analysis of SNPs in TF and TFPI between the survivor and nonsurvivor groups
Gene Survivor Nonsurvivor Allelic comparison Genotypic comparison
SNP P1adj OR
1










rs1324214 0.06 0.73 (0.53 to 1.01) 0.12 0.78 (0.56 to 1.16) 0.13 0.24
CC 165 (55%) 103 (62.8%)
CT 118 (39.3%) 57 (34.8%)
TT 17 (5.7%) 4 (2.4%)
T 448 (74.7%) 263 (80.2%)
C 152 (25.3%) 65 (19.8%)
rs762484 0.13 0.75 (0.51 to 1.09) 0.26 0.78 (0.82 to 1.07) 0.32 0.38
TT 208 (68.6%) 124 (74.7%)
TC 85 (28%) 39 (23.5%)
CC 10 (3.3%) 3 (1.8%)
T 501 (82.7%) 287 (86.4%)
C 105 (17.3%) 45 (13.6%)
rs696619 0.23 0.84 (0.63 to 1.12) 0.38 0.86 (0.73 to 1.09) 0.41 0.52
AA 122 (40.4%) 75 (45.7%)
AG 156 (51.7%) 80 (48.8%)
GG 24 (7.9%) 9 (5.5%)
A 400 (66.2%) 230 (70.1%)
G 204 (33.8%) 98 (29.9%)
rs3917615 0.00015 0.50 (0.35 to 0.72) 0.0018 0.69 (0.45 to 0.82) 0.00014 0.0017
CC 167 (55.1%) 123 (74.5%)
CT 126 (41.6%) 39 (23.6%)
TT 10 (3.3%) 3 (1.8%)
C 460 (75.9%) 285 (86.4%)
T 146 (24.1%) 445 (13.6%)
rs1361600 0.000049 0.48 (0.33 to 0.69) 0.00045 0.57 (0.41 to 0.74) 0.000024 0.00065
AA 164 (53.6%) 124 (74.7%)
AG 130 (42.5%) 38 (22.9%)
GG 12 (3.9%) 4 (2.4%)
A 458 (74.8%) 286 (86.1%)
G 154 (25.2%) 46 (13.9%)
rs958587 0.0001 0.50 (0.34 to 0.71) 0.0015 0.67 (0.43 to 0.79) 0.000094 0.0016
CC 164 (53.9%) 122 (73.9%)
CT 130 (42.8%) 40 (24.2%)
TT 10 (3.3%) 3 (1.8%)
C 458 (75.3%) 284 (86%)
T 150 (24.7%) 46 (14%)
rs3917643 0.62 1.84 (0.26 to 13.10) 0.78 1.48 (0.76 to 14.07) 0.62 0.78
AA 304 (99.3%) 165 (98.8%)
AG 2 (0.7%) 2 (1.2%)
A 610 (99.7%) 332 (99.4%)
G 2 (0.3%) 2 (0.6%)
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Table 3 Association analysis of SNPs in TF and TFPI between the survivor and nonsurvivor groups (Continued)
rs145977586 1.00 0.92 (0.08 to 10.14) 0.95 0.93 (0.12 to 12.76) 1.00 0.95
GG 304 (99.3%) 166 (99.4%)
GA 2 (0.7%) 1 (0.6%)
G 610 (99.7%) 333 (99.7%)
A 2 (0.3%) 1 (0.3%)
TFPI
rs3755248 0.75 0.94 (0.63 to 1.39) 0.62 0.84 (0.56 to 1.23) 0.13 0.11
TT 222 (72.8%) 126 (76.4%)
TC 80 (26.2%) 34 (20.6%)
CC 3 (1%) 5 (3%)
T 524 (85.9%) 286 (86.7%)
C 86 (14.1%) 44 (13.3%)
rs3213739 0.16 0.82 (0.62 to 1.08) 0.25 0.85 (0.72 to 1.04) 0.44 0.52
GG 135 (44.7%) 84 (50.9%)
GT 84 (27.8%) 41 (24.8%)
TT 83 (27.5%) 40 (24.2%)
G 354 (58.6%) 209 (63.3%)
T 250 (41.4%) 121 (36.7%)
rs7594359 0.18 0.78 (0.54 to 1.12) 0.12 0.71 (0.46 to 1.09) 0.23 0.18
CC 197 (64.8%) 120 (71.9%)
CT 104 (34.2%) 45 (26.9%)
TT 3 (1%) 2 (1.2%)
C 498 (81.9%) 285 (85.3%)
T 110 (18.1%) 49 (14.7%)
rs10931292 0.44 0.89 (0.67 to 1.19) 0.47 0.91 (0.81 to 1.13) 0.38 0.49
TT 142 (47%) 87 (52.7%)
TC 122 (40.4%) 56 (33.9%)
CC 38 (12.6%) 22 (13.3%)
T 406 (67.2%) 230 (69.7%)
C 198 (32.8%) 100 (30.3%)
rs8176441 0.87 1.03 (0.75 to 1.40) 0.95 0.92 (0.61 to 1.32) 0.06 0.17
TT 185 (60.9%) 90 (55.6%)
TC 89 (29.3%) 63 (38.9%)
CC 30 (9.8%) 9 (5.5%)
T 459 (75.5%) 243 (75%)
C 149 (24.5%) 81 (25%)
rs12613071 0.91 1.02 (0.76 to 1.37) 0.72 1.12 (0.83 to 1.58) 0.32 0.21
TT 150 (50.2%) 86 (52.8%)
TC 124 (41.5%) 58 (35.6%)
CC 25 (8.4%) 19 (11.7%)
T 424 (70.9%) 230 (70.6%)
C 174 (29.1%) 96 (29.4%)
rs10153820 0.20 1.21 (0.91 to 1.61) 0.45 1.15 (0.82 to 1.46) 0.25 0.52
CC 161 (53.5%) 76 (45.8%)
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Table 3 Association analysis of SNPs in TF and TFPI between the survivor and nonsurvivor groups (Continued)
CT 105 (34.9%) 70 (42.2%)
TT 35 (11.6%) 20 (12%)
C 427 (70.9%) 222 (66.9%)
T 175 (29.1%) 110 (33.1%)
rs8176592 0.35 0.81 (0.52 to 1.26) 0.62 0.84 (0.71 to 1.19) 0.34 0.58
TT 234 (77%) 133 (81.6%)
TC 68 (22.4%) 28 (17.2%)
CC 2 (0.6%) 2 (1.2%)
T 536 (88.2%) 294 (90.2%)
C 72 (11.8%) 32 (9.8%)
rs2192824 0.48 0.89 (0.64 to 1.24) 0.52 0.91 (0.72 to 1.19) 0.38 0.41
CC 190 (62.9%) 106 (63.9%)
CT 94 (31.1%) 55 (33.1%)
TT 18 (6%) 5 (3%)
C 474 (78.5%) 267 (80.4%)
T 130 (21.5%) 65 (19.6%)
Data presented as number (%) of subjects. P was determined using the chi-square test. Padj and ORadj came from multivariate logistic regression. P <0.0029 (0.05/
17) was considered statistically significant after Bonferroni correction. CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism; TF, tissue factor;
TFPI, tissue factor pathway inhibitor.
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ation with TF serum concentration (adjusted P = 0.02).
Moreover, we found that the plasma level of TF on
the first day of severe sepsis was higher in patients
who died than in survivors (3,036.3 ± 423.8 pg/ml vs.
1,650.7 ± 316.7 pg/ml, adjusted P =0.01).Figure 1 Kaplan–Meier survival analysis of patients with severe
sepsis according to the genotypes of rs1361600. Differences
between groups were compared by log-rank analysis. Kaplan–Meier
30-day survival curves showed strong significant differences between
the subjects who carried the AA genotype and the subjects who
carried the AG+ GG genotypes (P = 5.92 × 10-5).Discussion
To the best of our knowledge, this is the first study
testing the association between severe sepsis and the
polymorphisms of TF and TFPI in Chinese Han populations.
We found that the TF rs1361600 (−603)G allele, tagging
the –603G/–1322 T/–1812 T haplotype in the promoter
of TF, is associated with the clinical outcome in patients
with severe sepsis. Further evidence of the role of the
rs1361600G allele in the pathogenesis of severe sepsis is
provided by the observed significant association of this
allele with decreased TF mRNA transcription in vitro.
Moreover, severe sepsis patients with the rs1361600G
allele showed lower serum TF levels. In addition, we found
that the plasma levels of TF in patients with severe sepsis
are positively related to poor outcome.
Over the last decade, the cross-talk between inflammation
and coagulation systems emerged as a major mechanism
controlling the host response to the invading microorgan-
isms, and poor regulation of this mechanism was held
responsible for the occurrence of multiple organ failure and
eventually death in patients with severe sepsis [3]. Recent
studies indicated that most patients with severe sepsis had
coagulation abnormalities and the higher levels of TF, the
main regulator of coagulation process, were closely related
with the severity and outcome of sepsis [4]. Our results
showed that the plasma levels of TF are significantly
higher in nonsurviving septic patients than in surviving
septic patients. Exaggerated and uncontrolled coagu-
lation response to the infecting pathogens may lead
to microvascular thrombosis and multiple organ dys-
function syndrome [25,26]. In models of endotoxemia,
Figure 3 Association of tissue factor levels and rs1361600
genotypes in severe sepsis patients. Tissue factor (TF) serum
levels in severe sepsis patients were expressed as the median,
interquartile range and extremes. The TF levels were significantly
different between individuals with AG + GG and AA genotypes
(P = 0.005). The difference remained significant (adjusted P = 0.02)
after adjustment for age, gender, Acute Physiology and Chronic
Health Evaluation II and Sequential Organ Failure Assessment
scores in a linear regression model.
Figure 2 Association of tissue factor mRNA levels and
rs1361600 genotypes in healthy volunteers. The tissue factor (TF)
mRNA levels of peripheral blood mononuclear cells expressed as the
median, interquartile range and extremes. The TF mRNA levels were
significantly different between individuals with the AG + GG and the
AA genotypes under the lipopolysaccharide-stimulated condition
(P = 0.0012).
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protein C exhibited increased tissue fibrin deposition and
mortality compared with wild-type controls, presumably
due to reduced levels of antithrombin III and active
protein C [27]. Pawlinski and colleagues found that
reduced expression of TF resulted in diminished
LPS-induced coagulation, inflammation and mortality
[5]. All of these studies illustrate that downregulation
of any protein involved in hemostasis had a dramatic
effect on the whole immune response and influenced
sepsis-related mortality. Among several molecules involved
in the coagulation complex, TF had an important role
in the initiation of coagulation and in thrombin activation
at the site of inflammation [10]. TF is a 47 kDa membrane-
bound protein that is expressed in a wide variety of tissues,
including circulating blood cells, vascular endothelial cells
and hematopoietic cells. TF is considered responsible
for the initiation of coagulation in sepsis [28]. Apart
from its function in the coagulation system, TF attracted
considerable attention as a potential mediator in intracellu-
lar signaling of established inflammatory pathways, func-
tioning as an intermediate for factor VIIa-induced activation
of mitogen-activated protein kinases and calcium signaling.These effects were probably mediated by binding of
TF to protease activated receptor-1 and protease activated
receptor-2 on various cell types [29,30].
The TF gene is located at chromosome 1p21.3. The
involvement of TF in pathological processes may be
modulated by genetic factors influencing TF expression
and activity. Several common variants within the TF gene
have been described [31], such as two haplotypes
formed by the four completely concordant promoter
polymorphisms C-1812 T (rs958587), C-1322 T (rs3761955),
Del-1208Ins (rs ID not available) and A-603G (rs1361600).
Although not in a fully conclusive manner, these promoter
haplotypes were associated with TF expression levels and/or
activity as well as to thrombotic and atherosclerosis risk in
several studies [18,19,21]. However, to our knowledge, until
now no study has investigated the role of genetic variation
of TF in the risk of severe sepsis. In the present study, we
found that severe sepsis patients with the TF-rs1361600G
allele had a higher rate of survival at 30 days. The associ-
ation between severe sepsis death and rs1361600 may be
partly explained by differentiated expression of TF mRNA
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ther the rs1361600 A or G allele. The G allele was associ-
ated with a lower expression of TF mRNA in LPS-induced
samples. Our findings are in accordance with the result
from Terry and colleagues that the −1208I allele, in perfect
linkage disequilibrium with rs1361600G, was associated
with lower expression and activity of TF in human umbilical
vein endothelial cells induced by interleukin-1 or phorbol
12-myristate 13-acetate [32]. Moreover, we found that
circulating plasma levels of TF in severe sepsis patients
with the AG+GG genotype of rs1361600 were signifi-
cantly lower than those with the AA genotype. As TF
plays a pivotal role in the pathogenesis of severe sepsis in
response to infection, it is reasonable to assume that
patients with the rs361600A allele might produce a
higher amount of TF, and thereby enhance vascular TF ex-
pression to initiate coagulation and promote microvascular
thrombosis, which contributes to organ injury during
severe sepsis.
Our study has several clear strengths. First, mild sepsis
patients served as controls in our study. Such controls
were preferable to healthy individuals since a proportion
of healthy subjects might develop severe sepsis under the
stimulus of infection. Second, to minimize racial admix-
ture, we focused on central Han Chinese patients, which
could be regarded as one single homogeneous population.
Of note, there were two limitations to the current
study. First, although we had adequate power to detect
rs1361600 association with severe sepsis using the current
data, independent samples were still needed to validate the
associations. Second, we did not resequence the TF and
TFPI genes. Instead, only 17 SNPs including two functional
SNPs were genotyped in our study, which was far from
comprehensive. Some important SNPs might possibly
therefore have been missed or the observed association
might be due to other polymorphisms in linkage disequilib-
rium with the studied ones.
Conclusion
In summary, our results indicate that genetic variations
in the promoter region of TF are associated with the
outcome of severe sepsis in Chinese Han population
through influencing the TF mRNA expression. These
data support the concept that genetic variation in the
hemostatic gene plays an important role in the development
and outcome of severe sepsis. Identifying these genetic
factors might, in the future, help to choose appropriate
therapy for patients at different risk.
Key messages
 Individuals carrying the G allele of rs1361600 in the
TF gene have a lower risk for death of severe sepsis
in Chinese Han population. SNP rs1361600 influences the expression of TF
mRNA and the protein production of TF in patients
with severe sepsis.
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